Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Income: 2013-2025

Historic Operating Income for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.3 million.

  • Coherus Oncology's Operating Income rose 5.38% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of -$111.7 million for FY2024, which is 45.05% up from last year.
  • Coherus Oncology's Operating Income amounted to -$44.3 million in Q3 2025, which was up 2.53% from -$45.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Operating Income registered a high of $42.6 million during Q4 2024, and its lowest value of -$167.4 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Income was -$45.4 million (2025), whereas its average is -$40.9 million.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 509.51% in 2021, then soared by 161.83% in 2024.
  • Coherus Oncology's Operating Income (Quarterly) stood at -$39.5 million in 2021, then crashed by 30.21% to -$51.5 million in 2022, then crashed by 33.81% to -$68.9 million in 2023, then skyrocketed by 161.83% to $42.6 million in 2024, then climbed by 5.38% to -$44.3 million in 2025.
  • Its Operating Income was -$44.3 million in Q3 2025, compared to -$45.5 million in Q2 2025 and -$45.4 million in Q1 2025.